USPTO allows antibody patent claims

The United States Patent and Trademark Office (USPTO) has allowed genus claims for antibodies, a development enabled by Integral Molecular's Paratope-PLUS™ CDR-Scanning technology. This significant patent allowance is a major step for Integral Molecular, reinforcing its position in antibody discovery and engineering. The decision could pave the way for broader intellectual property protection in the field of antibody therapeutics, benefiting future research and development.